Novel Therapies Based on Mechanisms of HIV-1 Cell Entry
- 29 May 2003
- journal article
- review article
- Published by Massachusetts Medical Society in New England Journal of Medicine
- Vol. 348 (22) , 2228-2238
- https://doi.org/10.1056/nejmra022812
Abstract
Inhibitors of human immunodeficiency virus type 1 (HIV-1) enzymes are central to the treatment of HIV-1 infection, but the development of resistant viruses remains a problem. Another approach is to thwart the entry of the virus into cells by preventing the fusion of the viral envelope with the cell surface. This article reviews the way in which HIV-1 enters cells and potential means of denying the virus admission to cells.This publication has 94 references indexed in Scilit:
- A phase II clinical study of the long-term safety and antiviral activity of enfuvirtide-based antiretroviral therapyAIDS, 2003
- The Safety, Plasma Pharmacokinetics, and Antiviral Activity of Subcutaneous Enfuvirtide (T-20), a Peptide Inhibitor of gp41-Mediated Virus Fusion, in HIV-Infected AdultsAIDS Research and Human Retroviruses, 2002
- Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1Nature, 1996
- A Synthetic Peptide from HIV-1 gp41 Is a Potent Inhibitor of Virus-Mediated Cell—Cell FusionAIDS Research and Human Retroviruses, 1993
- A spring-loaded mechanism for the conformational change of influenza hemagglutininCell, 1993
- Retroviral Envelope Glycoproteins Contain a "Leucine Zipper"-like RepeatAIDS Research and Human Retroviruses, 1990
- A General Model for the Transmembrane Proteins of HIV and Other RetrovirusesAIDS Research and Human Retroviruses, 1989
- Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with the CD4 receptorCell, 1987
- T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAVNature, 1984
- The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirusNature, 1984